Ryan Chandanais, MS, CPhT
Ryan Chandanais, MS, CPhT
Ryan Chandanais is currently employed as an Emerging Therapeutics Analyst at a specialty pharmacy. His job is to gather, analyze, and present pipeline intelligence involving specialty drug products. He has additional drug development-related experience at a contract research organization for pre-clinical studies, where he served as a Research Associate and Report Coordinator. He holds a Master of Science in Integrative Pharmacology from Michigan State University and a Bachelor of Science in Education from Central Michigan University. He has acquired certifications as a Pharmacy Technician from the Pharmacy Technician Certification Board and a Laboratory Animal Technologist (LATG) from the American Association for Laboratory Animal Science.
Articles
Jul 2, 2018 @04:42 PM
Basket studies can be useful to determine if a drug targeting a certain genetic mutation at a particular site may be effective in treating that same genetic mutation found in cancer located in another site of the body.

Apr 11, 2018 @04:36 PM
The FDA has programs designed to expedite the drug development and review processes for promising pipeline products. The newest of these programs is Regenerative Medicine Advanced Therapy (RMAT).

Jan 30, 2018 @06:00 PM
Migraine is a condition characterized mainly by severe and recurrent headaches. Approximately 12% of the general population experiences migraines, with a higher frequency in women than men.

Dec 8, 2017 @08:09 AM
The FDA issues a CRL when it decides that an application does not meet all the requirements for approval.

Nov 16, 2017 @08:24 AM
Speeding up the review of drugs to treat serious diseases makes sense. Here is a look at how it works.

Nov 1, 2017 @02:38 AM
It takes a great deal of time and resources for a manufacturer to complete all the necessary requirements to submit a successful NDA to the FDA for review.

Oct 18, 2017 @01:55 AM
The most impactful of the FDA designations, this status may be applied to drugs used to treat serious or life-threatening conditions.

Dec 23, 2016 @03:09 AM
Priority review voucher program is designed to focus attention on otherwise neglected diseases.

Sep 13, 2016 @06:53 AM
A number of manufacturers are developing drugs to treat NASH, and approximately 95 drugs are in the pipeline worldwide at various stages of development.

May 26, 2016 @04:47 AM
Chimeric antigen receptor (CAR) T-cell therapy has generated a lot of buzz in the drug development world.